Clinical resistance of Staphylococcus keratitis to ciprofloxacin monotherapy

Indian Journal of Ophthalmology

Volumn 52, Issue 4, 2004, Pages 287-292

  Sharma, Vijay ^a   Sharma, Savitri ^b,c   Garg, Prashant ^c   Rao, Gullapalli N ^c  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b Hyderabad Eye Research Foundation   (India)

^c L V PRASAD EYE INSTITUTE   (India)

Author keywords

Ciprofloxacin; Keratitis; Resistance; S.aureus; Treatment

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CEFAZOLIN; CHLORAMPHENICOL; CIPROFLOXACIN; GENTAMICIN; OXACILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; BACTERIUM ISOLATE; CELL INFILTRATION; DISK DIFFUSION METHOD; DRUG RESPONSE; DRUG USE; EYE SURGERY; HUMAN; INDIA; KERATITIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PENETRATING KERATOPLASTY; RETROSPECTIVE STUDY; REVIEW; SLIT LAMP; STAPHYLOCOCCUS AUREUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; EYE INFECTIONS, BACTERIAL; FEMALE; HUMANS; INFANT; KERATITIS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 12244249207     PISSN: 03014738     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Dandona L, Dandona R, Naduvilath T, McCarty CA, Nanda A, Srinivas M, et al. Is current eye-care-policy focus almost exclusively on cataract adequate to deal with blindness in India? The Lancet 1998;351:1312-16.
2. Asbell P, Stenson S. Ulcerative keratitis: Survey of 30 years' laboratory experience. Arch Ophthalmol 1982;100:77-80.
3. Hyndiuk RA, Eiferman RA, Caldwell DR, Rosenwasser GO, Santos CI, Katz HR, et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ophthalmology 1996;103:1854-63.
4. O'Brien TP, Maguire MG, Fink NE, Alfonso E, McDonnell P and the bacterial keratitis study research group. Efficacy of ofloxacin versus cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the bacterial keratitis study research group. Arch Ophthalmol 1995;113:1257-65.
5. The Oflaxacin study group. Ofloxacin monotherapy for the primary treatment of microbial keratitis: A double - masked, randomised, controlled trial with conventional dual therapy. Ophthalmology 1997;104:1902-9.
6. Cambau E, Perani E, Dib C, Petinon C, Trias J, Jarlier V. Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem. Antimicrob Agent Chemotherap 1995;39:2248-52.
7. Poole K, Tetro K, Zhao Q, Neshat S, Heinrichs DE, Bianco N. Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression. Antimicrob Agent Chemotherap 1996;40:2021-28.
8. Garg P, Sharma S, Rao GN. Ciprofloxacin resistant Pseudomonas keratitis. Ophthalmology 1999;106:1319-23.
9. Snyder ME, Katz HR. Ciprofloxacin resistant bacterial keratitis. Am J Ophthalmol 1992;114:336-38.
10. Kunimoto DY, Sharma S, Garg P, Rao GN. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Emerging resistance. Ophthalmology 1999;106:80-85.
11. th edition. NCCLS Document M2-A7. Wayne, PA: NCCLS, 2000.
12. Tamashiro L. Broth microdilution MIC testing. Chapter 5.2. In: Isenberg HD, Editor. Clinical Microbiology Procedures Handbook, ASM Press, Washington DC, 1992. Vol.1, pp 5.2.18.
13. Jensen HG, Felix C. In vitro antibiotic susceptibilities of ocular isolates in North and South America. In vitro antibiotic testing group. Cornea 1998;17:79-87.
14. Ogawa GSH, Hyndiuk RA. Fluoroquinolones. Zimmerman TJ, et al (Editors.). Chapter 46. In: Textbook of Ocular Pharmacology. Philadelphia: Lippincott-Raven Publishers, Philadelphia, 1997. p 541.
15. Humphreys H, Mulvihill E. Ciprofloxacin resistant Staphylococcus aureus (letter). Lancet 1985;2:383.
16. Pieroni P, Goodfellow J, Reesor L, Louie M, Simor AE. Antimicrobial susceptibilities of blood culture isolates obtained before and after the introduction of ciprofloxacin. J Antimicrob Chemother 1997;39:419-22.
17. Maffett M, O'Day DM. Ciprofloxacin resistant bacterial keratitis (letter). Am J Ophthalmol 1993;155:545-46.
18. Goldstein MH, Kowalski RP, Gordon JY. Emerging fluoroquinolone resistance in bacterial keratitis. A 5 - year review. Ophthalmology 1999;106:1313-18.
19. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology 2000;107:1497-502.
20. Issacs RD, Kunke PJ, Cohan RL, Smith JW. Ciprofloxacin resistance in epidemic methicillin-resistance Staphylococcus aureus. Lancet 1988;2:843.
21. Insler MS, Fish LA, Silbernagel J, Hobden JA, O'Callaghan RJ, Hill JM. Successful treatment of methicillin-resistant Staphylococcus aureus keratitis with topical ciprofloxacin. Ophthalmology 1991;98:1690-92.
22. Callegan MC, Engel LS, Hill JM, Callaghan RJ. Ciprofloxacin versus tobramycin for the treatment of staphylococcal keratitis. Invest Ophthalmol Vis Sci 1994;35:1033-37.
23. Mathur SK, Singal S, Prasad KN, Kishore J, Ayyagiri A. Prevalence of methicillin resistant S.aureus in a tertiary care hospital. Ind J Med Microbiol 1994;12:96-101.
24. Sotozono C, Inagaki K, Koizumi N, Sano Y, Inatomi T, Kinoshita S. Methicillin resistant Staphylicoccus aureus and methicillin-resistant Staphylococcus epidermidis infections in the cornea. Cornea 2002;21:S94-101.